Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 25% ± 8% | |
macrophage | 5 studies | 25% ± 7% | |
microglial cell | 4 studies | 29% ± 5% | |
cardiac muscle cell | 4 studies | 21% ± 2% | |
GABAergic neuron | 4 studies | 33% ± 17% | |
interneuron | 4 studies | 35% ± 18% | |
oligodendrocyte | 4 studies | 23% ± 7% | |
adipocyte | 3 studies | 19% ± 2% | |
epithelial cell | 3 studies | 23% ± 6% | |
dendritic cell | 3 studies | 19% ± 3% | |
fibroblast | 3 studies | 18% ± 2% | |
transit amplifying cell | 3 studies | 27% ± 15% | |
glutamatergic neuron | 3 studies | 40% ± 15% | |
neuron | 3 studies | 26% ± 7% | |
astrocyte | 3 studies | 34% ± 10% | |
oligodendrocyte precursor cell | 3 studies | 30% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1087.34 | 1445 / 1445 | 100% | 36.98 | 183 / 183 |
liver | 100% | 1127.68 | 226 / 226 | 100% | 32.83 | 406 / 406 |
ovary | 100% | 1160.18 | 180 / 180 | 100% | 46.13 | 430 / 430 |
pancreas | 100% | 640.57 | 328 / 328 | 100% | 28.51 | 178 / 178 |
uterus | 100% | 1571.04 | 170 / 170 | 100% | 50.92 | 459 / 459 |
thymus | 100% | 1057.87 | 652 / 653 | 100% | 30.62 | 605 / 605 |
prostate | 100% | 1289.62 | 245 / 245 | 100% | 51.05 | 501 / 502 |
skin | 100% | 1330.49 | 1809 / 1809 | 100% | 39.15 | 471 / 472 |
kidney | 100% | 1234.99 | 89 / 89 | 100% | 30.78 | 898 / 901 |
stomach | 100% | 860.13 | 359 / 359 | 100% | 33.10 | 285 / 286 |
intestine | 100% | 1051.11 | 966 / 966 | 100% | 35.31 | 525 / 527 |
brain | 99% | 760.45 | 2628 / 2642 | 100% | 40.30 | 705 / 705 |
lung | 100% | 996.83 | 577 / 578 | 99% | 32.06 | 1148 / 1155 |
bladder | 100% | 1253.14 | 21 / 21 | 99% | 37.26 | 500 / 504 |
breast | 100% | 1288.03 | 459 / 459 | 99% | 33.46 | 1107 / 1118 |
adrenal gland | 100% | 772.25 | 258 / 258 | 98% | 24.22 | 226 / 230 |
adipose | 100% | 1214.85 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 30.01 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 64.20 | 29 / 29 |
muscle | 100% | 1317.21 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1318.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 58.04 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 34.01 | 1 / 1 |
blood vessel | 100% | 1199.16 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 1302.69 | 857 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 790.90 | 884 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001514 | Biological process | selenocysteine incorporation |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005525 | Molecular function | GTP binding |
GO_0000049 | Molecular function | tRNA binding |
GO_0043021 | Molecular function | ribonucleoprotein complex binding |
GO_0035368 | Molecular function | selenocysteine insertion sequence binding |
GO_0003746 | Molecular function | translation elongation factor activity |
GO_0003924 | Molecular function | GTPase activity |
Gene name | EEFSEC |
Protein name | Eukaryotic elongation factor, selenocysteine-tRNA specific (Selenocysteine-specific elongation factor) Selenocysteine-specific elongation factor (EC 3.6.5.-) (Elongation factor sec) (Eukaryotic elongation factor, selenocysteine-tRNA-specific) |
Synonyms | SELB |
Description | FUNCTION: Translation factor required for the incorporation of the rare amino acid selenocysteine encoded by UGA codons . Replaces the eRF1-eRF3-GTP ternary complex for the insertion of selenocysteine directed by the UGA codon . Insertion of selenocysteine at UGA codons is mediated by SECISBP2 and EEFSEC: SECISBP2 (1) specifically binds the SECIS sequence once the 80S ribosome encounters an in-frame UGA codon and (2) contacts the RPS27A/eS31 of the 40S ribosome before ribosome stalling . (3) GTP-bound EEFSEC then delivers selenocysteinyl-tRNA(Sec) to the 80S ribosome and adopts a preaccommodated state conformation . (4) After GTP hydrolysis, EEFSEC dissociates from the assembly, selenocysteinyl-tRNA(Sec) accommodates, and peptide bond synthesis and selenoprotein elongation occur . . |
Accessions | ENST00000483457.1 ENST00000644579.2 [P57772-1] P57772 ENST00000254730.11 [P57772-1] ENST00000644955.1 C9J8T0 |